Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

詳細記述

書誌詳細

出版年:	BMC Cancer
主要な著者:	Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
フォーマット:	論文
言語:	英語
出版事項:	BMC 2025-07-01
主題:	atezolizumab bevacizumab hepatocellular carcinoma real world immune checkpoint inhibitors
オンライン･アクセス:	https://doi.org/10.1186/s12885-025-14400-9